AstraZeneca Pharma India names Vinay Sharma as Business Unit Head

Published On 2024-03-26 08:42 GMT   |   Update On 2024-03-26 15:46 GMT
Advertisement

Bangalore: AstraZeneca Pharma India Limited has announced the appointment of Vinay Sharma as Business Unit Head - Rare Disease unit with effect from July 1, 2024.

"We wish to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Mr Vinay Sharma as Business Unit Head - Rare Disease unit with effect from July 1, 2024," the Company informed in a recent BSE filing.

Advertisement
Vinay Sharma is a Post‐Graduate in Marketing Management and Business Administration with over 23 years of rich industry experience. He joined AstraZeneca India in 2013 as Marketing Manager Diabetes. Over the last decade, years, he has held multiple sales, marketing, patient advocacy lead and leadership positions in AstraZeneca India and other international markets. He has been instrumental in leading the best-in-class launch of Forxiga in India. Currently, Mr. Vinay Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology.
Medical Dialogues team had earlier reported that AstraZeneca Pharma India Limited and Mankind Pharma Limited had entered into an agreement for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India.
AstraZeneca India was established in 1979 and is headquartered at Bengaluru, Karnataka. AstraZeneca Pharma India Limited (AZPIL) is the operating company and covers manufacturing, sales and marketing activities of the company in India. It is a listed company and is a subsidiary of AstraZeneca Plc, UK. 
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News